The Montreal Clinical Research Institute (IRCM) is proud to highlight the excellence of its researchers, who are recipients of the Cancer Research Society (CRS)’s 2025 Operating Grants. These grants, totaling $135,000 over two years, aim to support innovative projects designed to better prevent, detect, and treat all types of cancer.
The CRS has announced funding for 100 of the most promising projects across Canada, three of which come from IRCM:
Dr. Martin Sauvageau
Functional characterization of the long noncoding RNA CRNDE in colorectal cancer
This project investigates the role of the noncoding RNA CRNDE in colorectal cancer. This work could pave the way for new therapeutic approaches targeting genetic regulation in tumor cells.
Dre. Marlene Oeffinger
Determining the regulatory role of UFMylation along ribosomal DNA repair pathways
Her project aims to elucidate the role of UFMylation in ribosomal DNA repair, a key process for genetic stability. These findings could help identify new targets to combat cancer cell proliferation.
Dr. Nabil G. Seidah
The unique and synergistic roles of the convertases PCSK7 and PCSK9 in pancreatic cancer and associated liver metastasis
This research focuses on the enzymes PCSK7 and PCSK9, whose combined functions may influence the progression of pancreatic cancer and associated liver metastases. A deeper understanding of these mechanisms could lead to innovative strategies to slow the disease.
These grants underscore the quality and impact of the research conducted at IRCM to advance the fight against cancer and bring science closer to improving lives. Congratulations to our three researchers!
